Drugs / Glecaprevir / Pibrentasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05446857 | Apr 2023 → Apr 2024 | post-traumatic stress disorder | White River Junction Veterans Affairs Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glecaprevir / Pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05446857 ↗ |
| Route | Oral | “Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.” NCT05446857 ↗ |